1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Mologen AG - Product Pipeline Review - 2015

Mologen AG - Product Pipeline Review - 2015

  • October 2015
  • -
  • Global Markets Direct
  • -
  • 37 pages

Mologen AG - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Mologen AG - Product Pipeline Review - 2015’, provides an overview of the Mologen AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mologen AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Mologen AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Mologen AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Mologen AG’s pipeline products

Reasons to buy

- Evaluate Mologen AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Mologen AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Mologen AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Mologen AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mologen AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Mologen AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Mologen AG - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Mologen AG Snapshot 5
Mologen AG Overview 5
Key Information 5
Key Facts 5
Mologen AG - Research and Development Overview 6
Key Therapeutic Areas 6
Mologen AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Mologen AG - Pipeline Products Glance 10
Mologen AG - Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
Mologen AG - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Mologen AG - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Mologen AG - Drug Profiles 14
MGN-1703 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
MGN-1601 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
MGN-1404 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
MGN-1331 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
MGN-1333 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Oligonucleotide to Activate TLR-9 for Infectious Disease and Oncology 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Mologen AG - Pipeline Analysis 24
Mologen AG - Pipeline Products by Target 24
Mologen AG - Pipeline Products by Route of Administration 25
Mologen AG - Pipeline Products by Molecule Type 26
Mologen AG - Pipeline Products by Mechanism of Action 27
Mologen AG - Recent Pipeline Updates 28
Mologen AG - Dormant Projects 34
Mologen AG - Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables
Mologen AG, Key Information 5
Mologen AG, Key Facts 5
Mologen AG - Pipeline by Indication, 2015 7
Mologen AG - Pipeline by Stage of Development, 2015 8
Mologen AG - Monotherapy Products in Pipeline, 2015 9
Mologen AG - Phase III, 2015 10
Mologen AG - Phase II, 2015 11
Mologen AG - Phase I, 2015 12
Mologen AG - Preclinical, 2015 13
Mologen AG - Pipeline by Target, 2015 24
Mologen AG - Pipeline by Route of Administration, 2015 25
Mologen AG - Pipeline by Molecule Type, 2015 26
Mologen AG - Pipeline Products by Mechanism of Action, 2015 27
Mologen AG - Recent Pipeline Updates, 2015 28
Mologen AG - Dormant Developmental Projects,2015 34

List of Figures
Mologen AG - Pipeline by Top 10 Indication, 2015 7
Mologen AG - Pipeline by Stage of Development, 2015 8
Mologen AG - Monotherapy Products in Pipeline, 2015 9
Mologen AG - Pipeline by Top 10 Target, 2015 24
Mologen AG - Pipeline by Top 10 Route of Administration, 2015 25
Mologen AG - Pipeline by Top 10 Molecule Type, 2015 26
Mologen AG - Pipeline Products by Top 10 Mechanism of Action, 2015 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.